Thyrocare Technologies Ltd
NSE: THYROCARE BSE: 539871
₹389.95
(-1.52)%
Tue, 03 Feb 2026, 02:03 pm
Market Cap63.28B
PE Ratio45.12
Dividend2.35
Health Services
Medical/Nursing Services
24.5KAnalysis
dividend
- Dividends after 3 years are expected to be well covered by earnings (2x coverage).
- Unable to calculate sustainability of dividends as Thyrocare Technologies has not reported any payouts.
- Unable to evaluate Thyrocare Technologies's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Thyrocare Technologies's dividend against the top 25% market benchmark as the company has not reported any payouts.
future
- Thyrocare Technologies's earnings growth is expected to exceed the India market average.
- Thyrocare Technologies's earnings growth is expected to exceed the low risk savings rate of 7.2%.
- Thyrocare Technologies is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
- Performance (ROE) is expected to be above the current IN Healthcare industry average.
- An improvement in Thyrocare Technologies's performance (ROE) is expected over the next 3 years.
- Thyrocare Technologies's revenue growth is expected to exceed the India market average.
- Cash flow for Thyrocare Technologies is expected to decrease over the next 2 years.
- Thyrocare Technologies's earnings are expected to grow by 19.2% yearly, however this is not considered high growth (20% yearly).
- Thyrocare Technologies's earnings are expected to decrease over the next year.
- Thyrocare Technologies's net income is expected to increase but not above the 50% threshold in 2 years time.
- Thyrocare Technologies's revenue is expected to increase but not above the 50% threshold in 2 years time.
- Thyrocare Technologies's revenue is expected to grow by 8.3% yearly, however this is not considered high growth (20% yearly).
health
- Thyrocare Technologies is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Thyrocare Technologies is profitable, therefore cash runway is not a concern.
- Thyrocare Technologies is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (6705.2%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 60.9x debt.
- Thyrocare Technologies's cash and other short term assets cover its long term commitments.
- Interest payments on debt are well covered by earnings (EBIT is 76x coverage).
- Thyrocare Technologies's level of debt (0.7%) compared to net worth is satisfactory (less than 40%).
- High level of physical assets or inventory.
management
- The tenure for the Thyrocare Technologies board of directors is about average.
- Velumani's remuneration is lower than average for companies of similar size in India.
- Velumani's compensation has been consistent with company performance over the past year, both up more than 20%.
past
- Thyrocare Technologies's year on year earnings growth rate has been positive over the past 5 years.
- Thyrocare Technologies used its assets more efficiently than the IN Healthcare industry average last year based on Return on Assets.
- Thyrocare Technologies has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
- Thyrocare Technologies has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
- Thyrocare Technologies's 1-year earnings growth is less than its 5-year average (3.8% vs 14.7%)
- Thyrocare Technologies's earnings growth has not exceeded the IN Healthcare industry average in the past year (3.8% vs 14.4%).
value
- THYROCARE outperformed the Healthcare industry which returned 8.5% over the past year.
- THYROCARE outperformed the Market in India which returned -14.8% over the past year.
- Thyrocare Technologies's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- Thyrocare Technologies's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- Thyrocare Technologies is overvalued based on assets compared to the IN Healthcare industry average.
- Thyrocare Technologies is poor value based on expected growth next year.
- Thyrocare Technologies is overvalued based on earnings compared to the IN Healthcare industry average.
- Thyrocare Technologies is overvalued based on earnings compared to the India market.
- NSEI:THYROCARE is flat (0.5%) underperforming the Healthcare industry which returned 5.1% over the past month.
- NSEI:THYROCARE is flat (0.5%) underperforming the market in India which returned 9% over the past month.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800